相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Emerging bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia: one step ahead ibrutinib
Stefano Molica et al.
EXPERT OPINION ON EMERGING DRUGS (2020)
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Daniela Angst et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Scaffold hopping of the SYK inhibitor entospletinib leads to broader targeting of the BCR signalosome
Radek Jorda et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)
Yifan Feng et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2019)
Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)
Scott H. Watterson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review
Chengyuan Liang et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development
James J. y Crawford et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Design strategies, structure activity relationship insights for purines as kinase inhibitors
Sahil Sharma et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2016)
Small Molecule Reversible Inhibitors of Bruton's Tyrosine Kinase (BTK): Structure-Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)
George V. De Lucca et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Structure-Based Drug Design of RN486, a Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, for the Treatment of Rheumatoid Arthritis
Yan Lou et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Purine derivatives as potent Bruton's tyrosine kinase (BTK) inhibitors for autoimmune diseases
Qing Shi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinib
Amin Aalipour et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2014)
Targeting Bruton's tyrosine kinase in B cell malignancies
Rudi W. Hendriks et al.
NATURE REVIEWS CANCER (2014)
Functionalized Orthoesters as Powerful Building Blocks for the Efficient Preparation of Heteroaromatic Bicycles
Gulluzar Bastug et al.
ORGANIC LETTERS (2012)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
分享论文
